Identification of Risk Factors for Requiring Transfusion during Front-Line Chemotherapy for Ovarian Cancer

Author： Hensley M.L. Lebeau D. Leon L.F. Venkatraman E. Waltzman R. Sabbatini P. Almadrones L. Chi D. Spriggs D.

Publisher： Elsevier

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.81, Iss.3, 2001-06, pp. : 485-489

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Front-Line Treatment of Epithelial Ovarian Cancer: Focus on the Medical Oncologists Perspective

By Martin Lainie Schilder Russell J.

American Journal of Cancer, Vol. 4, Iss. 4, 2005-01 ,pp. : 221-231

Adis International

Access to resources Recommend Favorite

Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial

By Stathopoulos G. P. Katis C. Tsavdaridis D. Dimitroulis J. Karaindros D. Stathopoulos J. Dimou E.

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 555-560

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

By Bolis G. Scarfone G. Villa A. Parazzini F.

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite

Why Study Third-, Fourth-, Fifth-,...Line Chemotherapy of Ovarian Cancer?

By Markman M.

Gynecologic Oncology, Vol. 83, Iss. 3, 2001-12 ,pp. : 449-450

Elsevier

Access to resources Recommend Favorite

Risk Factors for Ovarian Cancer in Central Italy

By Greggi S. Parazzini F. Paratore M.P. Chatenoud L. Legge F. Mancuso S. La Vecchia C.

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 50-54

Elsevier

Access to resources Recommend Favorite